HELP UNLOCK URGENTLY NEEDED LDL-C CONTROL FOR YOUR PATIENTS WHO NEED ADDITIONAL LOWERING. ADD NEXLIZET.1-4

For appropriate patients currently on maximally tolerated statin therapy not at LDL-C goal1

Hypothetical patient. Individual results may vary.

56-year-old African
American female with
ASCVD

Nadine’s HCP has been seeing her over the course of 20 years

  • Has been trying to get her LDL-C under control for several years
    • Prescribed atorvastatin, which Nadine had trouble tolerating

  • Nadine suffered an MI one year ago
    • Post-MI, Nadine’s HCP initiated 20-mg rosuvastatin, but Nadine could not tolerate that either, so she was titrated down to 10-mg rosuvastatin

  • Father died of MI
  • Peripheral artery disease with claudication; receiving a P2Y12 inhibitor
  • Has maintained a healthy diet
  • Receiving 10-mg rosuvastatin
  • Diabetes mellitus with 6.2% HbA1c, receiving 500-mg metformin twice daily plus 10-mg empagliflozin once daily
Starting LDL-C: 185 mg/dL. Adding NEXLIZET: 67 mg/dL, under Guideline recommended goal of LDL-C under 70 mg/dL

FOR PATIENTS WITH CLINICALLY ESTABLISHED ASCVD,
GUIDELINES RECOMMEND7:

  • Reducing LDL-C by ≥50%
  • Intensifying therapy if LDL-C is ≥70 mg/dL

*Results based on up to a 52% LDL-C reduction with 10-mg rosuvastatin.5

Results based on a 23% LDL-C reduction with ezetimibe.1

Results based on a 36% LDL-C reduction with NEXLIZET.1

LDL-C=low-density lipoprotein cholesterol; ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia; MI=myocardial infarction; HbA1c=hemoglobin A1C.

References: 1. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 11/2020. 2. Data on file. CSR 1002-053. January 2019. 3. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032. 4. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780-1788. 5. CRESTOR. Prescribing information. AstraZeneca; 9/2020. 6. Data on file. Protocol: ETC-1002FDC-053. August 2018. 7. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.

Hypothetical patient. Individual results may vary.

42-year-old Hispanic
male with HeFH

Nathan’s HCP has been treating his elevated LDL-C for 17 years

  • Prescribed 2 different statins before arriving at atorvastatin
    • Initiated 40-mg atorvastatin

    • Titrated up to 80-mg atorvastatin

    • Nathan could not tolerate the higher dose, so he was titrated back down to 40-mg atorvastatin

  • Father died of MI at 49 years of age; grandfather died of stroke at 52 years of age
  • Elevated LDL-C since childhood and diagnosed with HeFH as an adult on the basis of LDL-C ≥190 mg/dL and presence of tendon xanthomas
  • Moderate exercise regimen
  • Has maintained a healthy diet; pescatarian for 10 years
  • Receiving 40-mg atorvastatin
  • Hypertensive: 118/82 mmHg; receiving 160-mg valsartan once daily
Starting LDL-C: 265 mg/dL. Adding NEXLIZET: 93 mg/dL, under Guideline recommended  goal of LDL-C under 100 mg/dL

FOR PATIENTS WITH HeFH, GUIDELINES RECOMMEND7:

  • Reducing LDL-C by ≥50%
  • Intensifying therapy if LDL-C is ≥100 mg/dL

*Results based on up to a 50% LDL-C reduction with 40-mg atorvastatin.5

Results based on a 23% LDL-C reduction with ezetimibe.1

Results based on a 36% LDL-C reduction with NEXLIZET.1

LDL-C=low-density lipoprotein cholesterol; ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia; MI=myocardial infarction.

References: 1. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 11/2020. 2. Data on file. CSR 1002-053. January 2019. 3. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032. 4. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780-1788. 5. LIPITOR. Prescribing information. Pfizer, Inc.; 11/2020. 6. Data on file. Protocol: ETC-1002FDC-053. August 2018. 7. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.

EXPLORE THE MOA OF NEXLIZET